Horizon will help develop the cell line-derived reference material, St. George's will provide clinical samples, and the EMQN will run a validation study.
The companies today launched four assays for the Chinese market for renal, liver, and cardiac testing for use on the Vitros 4600 and Vitros 5600 systems.
The firms will focus on developing and implementing biomarker-based immunoassay diagnostics for kidney injury.
Along with WHO, Mologic, and Leiden University Medical Center, FIND is developing two rapid diagnostic tests to detect circulating anodic antigen in blood or urine.
BeaconLBS' platform provides physicians with access to evidence-based guidelines and pricing information that can help guide test and lab facility selection.
Sona said it manufactures gold nanorods that could be integrated into the multiplexed lateral flow assays that Olm Diagnostics is developing.
Using BGI's sequencing technology, the firms plan to commercialize Natera's Signatera test in China and to develop reproductive health tests in "select markets."
Centogene said it will conduct molecular diagnostic testing using deletion/duplication analysis and full-length sequencing of the DMD gene.
Biocept will use its liquid biopsy assay to test cerebrospinal fluids of patients diagnosed with certain cancers and then compare results to standard methods.
The partnership will accelerate the development of molecular diagnostics in the Chinese market, Minneapolis-based Bio-Techne said.